AIDSmeds Founder Peter Staley interviewed Dr. Alan Tennenberg, Tibotec’s VP of Clinical Affairs, regarding the latest clinical data on Prezista, the newly approved protease inhibitor. We also asked him about how the company responded to community demands around pricing.

Click here to listen to the 7 minute interview.
(6.4MB mp3 file)